Patent classifications
A61F2250/0068
Ocular Device and Drug Delivery System, With Case
An ocular device for placement under an eyelid that includes a plate with a back surface having at least one protrusion having a convex contact surface to contact the sclera of the eye and to provide an offset space. The plate can be connected to an elongated support member. The ocular device can deliver a material to an eye of a user, including, for example, a pharmaceutically active agent. A case for holding and dispensing an ocular device includes a well configured to retain fluid, a stabilizer, and a lid. The lid is connected to the well and rotatable between a position covering the well and a position with the well uncovered. The lid can have a port for adding fluid to the well, and a receiver, which can hold an ocular device, can project from the lid.
Ocular systems, devices, and methods
Various embodiments are described herein for an ocular device implantable in a user's eye and which has an adjustable optical element for varying one or more optical properties for the eye such as, but not limited to, providing a dynamically adjustable aperture stop to control the amount of incoming light, filtering incoming light, polarizing incoming light, and/or varying a depth of field for the eye.
METHOD AND APPARATUS FOR CREATING A MODIFIED TISSUE GRAFT
In a method of creating a modified tissue graft, at least one exterior surface of a graft is modified by compressing, cutting and/or removing one or more portions thereof, such as to create designed surface features which cause the tissue graft to have characteristics for a specific anatomical area. The modified tissue graft may comprise a medicated graft, such as by associating medicants with the surface features, or by associating a second graft or layer with a modified base tissue graft layer, where medicants are associated with the second graft or layer. The tissue graft may be modified by pressing a specially configured template or die, such as having blades thereon, into the tissue graft, such as to create a pattern of partial depth cuts.
EXTRACELLULAR MATRIX DELIVERY DEVICE
The present disclosure relates to the field of endoscopy. Specifically, the present disclosure relates to systems and methods for delivering a therapeutic agent within a body lumen, and maintaining the therapeutic agent in contact with a wall of the body lumen for a beneficial period of time. In particular, the present disclosure relates to systems and methods to prevent lesions within the gastrointestinal tract from spreading into healthy surrounding tissue.
Wireless degradation data generator for use with a therapeutic scaffold and methods for use therewith
A degradation data generator is used with a scaffold for delivery within a patient. The degradation data generator includes a driving circuit electrically coupled to drive an impedance of the scaffold. A detection circuit generates degradation data based on the impedance of the scaffold or other properties such as RF or lightwave transmission, conductance or absorption. The degradation data indicates an amount of biodegradation of the scaffold. A wireless transmitter is coupled to transmit the degradation data to a wireless degradation data receiver, while the scaffold is within the patient.
Implants with controlled drug delivery features and methods of using same
Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
SYSTEMS, APPARATUS, AND METHODS FOR TRANSPORT AND DELIVERY OF THERAPEUTIC SUBSTANCE TO MIDDLE EAR
Systems, apparatus, and methods are described for transporting and delivering a therapeutic substance to an ear of a subject, including a tubular element (216) configured for deployment in a tympanic membrane (TM) and a fluid transport element (230). The fluid transport element can be configured to transport the therapeutic substance from a proximal side to a distal side of the tubular element. Systems, apparatus, and methods further can include a fluid dispenser including a reservoir configured to contain a therapeutic substance, and a tubular element defining a lumen in fluid communication with an outlet in which the lumen and the outlet are configured to deliver the therapeutic substance from the reservoir to a region proximal to the tympanic membrane. Systems, apparatus, and methods further can include an electrode device.
Methods and systems for treating intracranial hypertension and related indications using an optic nerve stent or shunt
Embodiments of the present specification provide surgical methods and apparatuses to deploy at least one stent through an optic nerve sheath in order to maintain an opening/fenestration for intracranial fluid egress. The surgical method creates a fenestration, an opening, a slit, or a hole, through an optic nerve sheath of a human patient. The fenestration is created in a minimally invasive manner using an applicator, such as an endoscopic visualization apparatus, that includes a stent or shunt for deploying through the fenestration. The presently disclosed specification is indicated to treat papilledema and/or intracranial hypertension and to deliver therapeutic compositions through the optic nerve sheath.
A Degradable Vascular Stent Capable Of Avoiding Late Restenosis
The present invention relates to a degradable vascular stent capable of avoiding late restenosis, comprising a base region formed by a polylactic acid based polymer; at least one storage region in which an active agent is stored; and an outer layer of a drug sustained release coating covered on the base region and/or the storage region. Before the mass of the polylactic acid based polymer is decreased by 10-20%, the active agent is retained in structural units of the polylactic acid based polymer. After the mass of the polylactic acid based polymer is decreased by 10-20%, the active agent is released from the storage region. The base region provides a supporting capacity for ensuring patency of blood vessels; the drug sustained release coating is used for drug release in an early stage; and the active agent only works in late degradation of the stent to avoid late restenosis.
Graft material having selectively advanced permeability structure and method
A laser is used to form openings within a graft material to selectively enhance permeability of a prosthesis for tissue integration therein. A feature of utilizing a laser to create the openings for tissue integration builds from its tunability. More particularly, the laser precisely places openings in any pattern and location, and on any textile that forms the graft material. Further, the power and focus of the laser is precisely adjusted to control the diameter and shape of the openings. All parameters of the openings can be controlled at will, allowing for the opportunity to selectively enhance and optimize the permeability of the graft material in a vessel.